SlideShare a Scribd company logo
1 of 25
Anti-psychotics II
Brian J. Piper, Ph.D., M.S.
   piperbj@husson.edu




                February 4, 2013
Goals
• Pharmacy students should be able to:
  – describe the MOA and adverse effects of second
    generation antipsychotics
  – evaluate the relative pros and cons (acute and
    long-term) of first and second generation
    antipsychotics
DSM5 Diagnosis of Schizophrenia
• Two or more of the following, including 1, 2, or 3
   1.   Delusions
   2.   Hallucinations
   3.   Disorganized speech
   4.   Grossly abnormal psychomotor behavior
   5.   Negative symptoms
• Duration: 1 month during last 6
• Social/occupational dysfunction
• Exclusion: medical condition or drug
Atypical (Second Generation)
    • Mechanism of Action
         – Dissociate more rapidly from the D2 receptor




Stahl, S. (2008). Essential Psychopharmacology, p. 369-370.
MOA of Atypical Antipsychotics
    • Dissociate more rapidly from the D2 receptor
         – ↓ acute EPS, ↓ hyperprolactinemia




Stahl, S. (2008). Essential Psychopharmacology, p. 371.
MOA of Atypicals
    • Atypicals
         – Dissociate more rapidly from the D2 receptor
         – Block the 5-HT2A (and so many other!) receptors




Stahl, S. (2008). Essential Psychopharmacology, p. 384.
5-HT2A
    • Hallucinogens = 5-HT2A agonists
    • Receptor Distribution: cortex


 [11C]MDL100,907




Meyer et al. (2010). Neuroimage, 50(3), 984-993.
Brain Morphology & Schizophrenia
    Some schizophrenia patients exhibit
  morphological changes in the brain like
   enlargement of fluid-filled ventricles.
Adverse Effect of Atypicals I: Weight Gain
Weight Gain & Olanzapine
    Weight Gain                                    % of Patients
    Relative to Baseline (1.6 yrs)
    > 7%                                           64%
    > 15%                                          32%
    > 25%                                          12%




Citrome et al. (2011). Journal of Clinical Investigation, 31(7), 455-482.
Risks with long-term Atypicals
       Mechanism: 5-HT2C

           Mechanism: X




                           $515 Million
Concern
 • Adult monkeys received
   FGA (haloperidol) or                                            *
   SGA (olanzapine)                                                    *
   antipsychotics for 2
   years at doses similar to
   schizophrenics.
 • Gray matter in parietal
   cortex was examined.


Konopaske et al. (2007). Neuropsychopharmacology, 32, 1216-1223.
Do antipsychotics cause neurostructural
                           changes?

 Repeated MRI of schizophrenics
 Ventricular volume change
 (slope) by antipsychotic
 treatment
      – most (+.39)
      – intermediate (+.36)
      – least (+.16)




Beng-Choon et al. (2011). Archives of General Psychiatry, 68(2), 128-137.
Do antipsychotics cause neurostructural
                           changes?

 Repeated MRI of
 schizophrenics
 White matter change
 (slope) by antipsychotic
 treatment
     – most (-.64)
     – intermediate (-.51)
     – least (+1.30)




Beng-Choon et al. (2011). Archives of General Psychiatry, 68(2), 128-137.
Practice Makes Perfect
• FGA:
 http://www.howjsay.com/index.php?word=perphenazine&submit=Submit
• SGA:
  – http://www.howjsay.com/index.php?word=ziprasidone&submit=Submit
  – http://www.howjsay.com/index.php?word=quetiapine&submit=Submit
  – http://www.howjsay.com/index.php?word=risperidone&submit=Submit
Clinical Antipsychotic Trials for
        Intervention Effectiveness) CATIE
    • 18-month randomized, double-blind trial of FGA & SGAs in real-world
      (N=1,432) funded by non-industry (NIMH)



                     Perphenazine   Olanzapine   Risperidone   Ziprasidone   Quetiapine

   Discontinuation
   Rate
                     75%            64%          74%           79%           82%
   Weight Change
   (lbs/month)
                     -0.2           +2.0         +0.4          -0.3          +0.5

   Change in
   Cholesterol
                     +1.5           +9.4         -1.3          -8.2          +6.6
   Change in
   Prolactin
                     =              =            ↑             =             =
Lieberman et al. (2005). New England Journal of Medicine, 353(12), 1209-1223.
CATIE Findings
    • FGAs & SGAs showed similar efficacy with a
      slight advantage for olanzapine.
    • Olanzapine showed a higher metabolic risk
      relative to both FGA and other SGAs.

Black Box For All SGAs
Cognitive Behavioral Therapy
    • Antipsychotics show limited efficacy for negative symptoms & many
      patients continue to exhibit hallucinations & delusions
    • Cognitive Behavioral Therapy is a short-term, empirically based
      psychotherapy developed by Aaron “Tim” Beck (left) that is used with
      antipsychotics.




        1921 -
Rector & Beck (2012). J Nervous & Mental Disease, 200(10), 832-839.
Onset Age
• Males: early 20s
• Females: late 20s
Schizophrenia in Children
    • More frequently recognized
    • Example (0 to 3 min):
      http://www.youtube.com/watch?v=UTU
      Mt05_nCI




:
Summary
• SGAs produce less acute EPS than FGA but
  also cause diabetes.
• No clear consensus exists in the choice
  between FGA and SGA.
• Using agents at above recommended doses or
  combining drugs are common clinically but are
  not well studied.
Receptor/Adverse Effect
        X: diabetes
        M1: sedation
        H1: sedation, appetite
        α1: sedation
        5-HT2C: appetite




Stahl, S. (2008). Essential Psychopharmacology, p. 384.
Self-Test #1
     • _________ were the top selling drugs in 2009.
         – A) antipsychotics
         – B) oncology agents
         – C) antidiabetics
         – D) respiratory agents
         – E) HIV antivirals




http://www.nytimes.com/2010/10/03/business/03psych.html?_r=4&hp=&pagewanted=all&
http://survivingantidepressants.org/index.php?/topic/2963-the-top-prescription-drugs-of-2011/
Self-Test #2
• If a family member were diagnosed with
  schizophrenia, what agent would you prefer
  they receive and why? Would this differ based
  on age or health?

More Related Content

What's hot

The Neurobiology of Depression (Dr Imran Waheed)
The Neurobiology of Depression (Dr Imran Waheed)The Neurobiology of Depression (Dr Imran Waheed)
The Neurobiology of Depression (Dr Imran Waheed)Imran Waheed
 
Treatment resistant schizophrenia
Treatment resistant schizophreniaTreatment resistant schizophrenia
Treatment resistant schizophreniaGAURAVUPPAL23
 
A Case Study on Schizophrenia
 A Case Study on Schizophrenia A Case Study on Schizophrenia
A Case Study on SchizophreniaReeba Sara Koshy
 
ADHD and Addiction: Diagnosis and Management
ADHD and Addiction: Diagnosis and ManagementADHD and Addiction: Diagnosis and Management
ADHD and Addiction: Diagnosis and ManagementJacob Kagan
 
Polypharmacy+in+Schizophrenia
Polypharmacy+in+SchizophreniaPolypharmacy+in+Schizophrenia
Polypharmacy+in+Schizophreniadhavalshah4424
 
Post stroke depression
Post stroke depressionPost stroke depression
Post stroke depressiondrsherifsaad
 
OPIOID SUBSTITUTION THERAPY.ppt
OPIOID SUBSTITUTION THERAPY.pptOPIOID SUBSTITUTION THERAPY.ppt
OPIOID SUBSTITUTION THERAPY.pptRaghunathManna4
 
Cardiovascular and metabolic side effects of antipsychotics
Cardiovascular and metabolic side effects of antipsychoticsCardiovascular and metabolic side effects of antipsychotics
Cardiovascular and metabolic side effects of antipsychoticsPawan Sharma
 
Management of treatment-resistant schizophrenia
Management of treatment-resistant schizophreniaManagement of treatment-resistant schizophrenia
Management of treatment-resistant schizophreniaismail sadek
 
Autoimmune Encephalitis
Autoimmune EncephalitisAutoimmune Encephalitis
Autoimmune EncephalitisNeha Rai
 
Postictal psychosis - a complex challenge
Postictal psychosis - a complex challengePostictal psychosis - a complex challenge
Postictal psychosis - a complex challengeYasir Hameed
 

What's hot (20)

692 ADHD PowerPoint
692 ADHD PowerPoint692 ADHD PowerPoint
692 ADHD PowerPoint
 
Dementia Power. Point
Dementia Power. PointDementia Power. Point
Dementia Power. Point
 
The Neurobiology of Depression (Dr Imran Waheed)
The Neurobiology of Depression (Dr Imran Waheed)The Neurobiology of Depression (Dr Imran Waheed)
The Neurobiology of Depression (Dr Imran Waheed)
 
Treatment resistant schizophrenia
Treatment resistant schizophreniaTreatment resistant schizophrenia
Treatment resistant schizophrenia
 
Alzheimer's disease
Alzheimer's disease Alzheimer's disease
Alzheimer's disease
 
Approach to Dementia
Approach to DementiaApproach to Dementia
Approach to Dementia
 
A Case Study on Schizophrenia
 A Case Study on Schizophrenia A Case Study on Schizophrenia
A Case Study on Schizophrenia
 
ADHD and Addiction: Diagnosis and Management
ADHD and Addiction: Diagnosis and ManagementADHD and Addiction: Diagnosis and Management
ADHD and Addiction: Diagnosis and Management
 
Glutamate & schizophrenia
Glutamate & schizophreniaGlutamate & schizophrenia
Glutamate & schizophrenia
 
Polypharmacy+in+Schizophrenia
Polypharmacy+in+SchizophreniaPolypharmacy+in+Schizophrenia
Polypharmacy+in+Schizophrenia
 
Post stroke depression
Post stroke depressionPost stroke depression
Post stroke depression
 
Escitalopram
EscitalopramEscitalopram
Escitalopram
 
OPIOID SUBSTITUTION THERAPY.ppt
OPIOID SUBSTITUTION THERAPY.pptOPIOID SUBSTITUTION THERAPY.ppt
OPIOID SUBSTITUTION THERAPY.ppt
 
Cardiovascular and metabolic side effects of antipsychotics
Cardiovascular and metabolic side effects of antipsychoticsCardiovascular and metabolic side effects of antipsychotics
Cardiovascular and metabolic side effects of antipsychotics
 
Depression and diabetes by Dr Shahjada Selim
Depression and diabetes by Dr Shahjada SelimDepression and diabetes by Dr Shahjada Selim
Depression and diabetes by Dr Shahjada Selim
 
Management of treatment-resistant schizophrenia
Management of treatment-resistant schizophreniaManagement of treatment-resistant schizophrenia
Management of treatment-resistant schizophrenia
 
Adhd
Adhd Adhd
Adhd
 
Autoimmune Encephalitis
Autoimmune EncephalitisAutoimmune Encephalitis
Autoimmune Encephalitis
 
Postictal psychosis - a complex challenge
Postictal psychosis - a complex challengePostictal psychosis - a complex challenge
Postictal psychosis - a complex challenge
 
Alzheimers disease
Alzheimers diseaseAlzheimers disease
Alzheimers disease
 

Viewers also liked (20)

Iloperidone
Iloperidone Iloperidone
Iloperidone
 
Antipsychotic drugs
Antipsychotic drugsAntipsychotic drugs
Antipsychotic drugs
 
Antipsychotics I
Antipsychotics IAntipsychotics I
Antipsychotics I
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
 
Overview of the Mechanism of Typical vs Atypical Antipsychotics
Overview of the Mechanism of Typical vs Atypical AntipsychoticsOverview of the Mechanism of Typical vs Atypical Antipsychotics
Overview of the Mechanism of Typical vs Atypical Antipsychotics
 
Typical antipsychotics
Typical   antipsychoticsTypical   antipsychotics
Typical antipsychotics
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
 
Antipsychotics - drdhriti
Antipsychotics - drdhritiAntipsychotics - drdhriti
Antipsychotics - drdhriti
 
"Zyprexa and the Prescribing Physician
"Zyprexa and the Prescribing Physician"Zyprexa and the Prescribing Physician
"Zyprexa and the Prescribing Physician
 
Olazapine
OlazapineOlazapine
Olazapine
 
Uses of Quetiapine
Uses of Quetiapine Uses of Quetiapine
Uses of Quetiapine
 
Clozaril
ClozarilClozaril
Clozaril
 
Review Primary Care
Review Primary CareReview Primary Care
Review Primary Care
 
Generic Zyprexa Tablets
Generic Zyprexa TabletsGeneric Zyprexa Tablets
Generic Zyprexa Tablets
 
Antisychotic Drugs
Antisychotic DrugsAntisychotic Drugs
Antisychotic Drugs
 
Clozapine
ClozapineClozapine
Clozapine
 
Seminar On Antidepressants
Seminar On AntidepressantsSeminar On Antidepressants
Seminar On Antidepressants
 
Adverse effects antipsychotics dr ali
Adverse effects antipsychotics dr aliAdverse effects antipsychotics dr ali
Adverse effects antipsychotics dr ali
 
Serotonergic system ravi
Serotonergic system raviSerotonergic system ravi
Serotonergic system ravi
 
Dopamine hypothesis
Dopamine hypothesisDopamine hypothesis
Dopamine hypothesis
 

Similar to Antipsychotics Part II

Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part IBrian Piper
 
Pharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersPharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersBrian Piper
 
What is ADHD? Update on pharmacology and neuroimaging
What is ADHD? Update on pharmacology and neuroimagingWhat is ADHD? Update on pharmacology and neuroimaging
What is ADHD? Update on pharmacology and neuroimagingYasir Hameed
 
Hanipsych, updates on neurobiology and neurotoxicity of depression
Hanipsych, updates on neurobiology and neurotoxicity of depressionHanipsych, updates on neurobiology and neurotoxicity of depression
Hanipsych, updates on neurobiology and neurotoxicity of depressionHani Hamed
 
New treatment trends in alzheimer disease
New treatment trends in alzheimer diseaseNew treatment trends in alzheimer disease
New treatment trends in alzheimer diseaseSarath Menon
 
Danielle.Degroot.Case Study Pp
Danielle.Degroot.Case Study PpDanielle.Degroot.Case Study Pp
Danielle.Degroot.Case Study PpDanielleDDI
 
The neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarThe neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarNick Stafford
 
A Multimodal, Regenerative Approach to Traumatic Brain Injury - OMED Oct 2020
A Multimodal, Regenerative Approach to Traumatic Brain Injury - OMED Oct 2020A Multimodal, Regenerative Approach to Traumatic Brain Injury - OMED Oct 2020
A Multimodal, Regenerative Approach to Traumatic Brain Injury - OMED Oct 2020Megan Hughes
 
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDPsychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDBrian Piper
 
Warren.Cognition.December.2008
Warren.Cognition.December.2008Warren.Cognition.December.2008
Warren.Cognition.December.2008Richard G. Petty
 
CBT_for_Bipolar_Disorder-Set_Available_for_Teaching.ppt
CBT_for_Bipolar_Disorder-Set_Available_for_Teaching.pptCBT_for_Bipolar_Disorder-Set_Available_for_Teaching.ppt
CBT_for_Bipolar_Disorder-Set_Available_for_Teaching.pptIqbalBaryar
 
Schizophrenia~Ketamine~Pterostilbene
Schizophrenia~Ketamine~PterostilbeneSchizophrenia~Ketamine~Pterostilbene
Schizophrenia~Ketamine~PterostilbeneDevender Palsa
 
Sublingual Immunotherapy From Efficacy, Safety to Practical Considerations
Sublingual Immunotherapy From Efficacy, Safety to Practical ConsiderationsSublingual Immunotherapy From Efficacy, Safety to Practical Considerations
Sublingual Immunotherapy From Efficacy, Safety to Practical ConsiderationsKSAAI
 
Sychosis and schizophrenia.pdf
Sychosis and schizophrenia.pdfSychosis and schizophrenia.pdf
Sychosis and schizophrenia.pdfsdfghj21
 
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...Fundación Ramón Areces
 
Psychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADPsychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADBrian Piper
 
Bogota delirium051110
Bogota delirium051110Bogota delirium051110
Bogota delirium051110hospira2010
 
Brexpiprazole Final Presentation
Brexpiprazole Final PresentationBrexpiprazole Final Presentation
Brexpiprazole Final PresentationNina Chacko
 
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptxRoberto Scarafia
 

Similar to Antipsychotics Part II (20)

Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part I
 
Pharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersPharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disorders
 
What is ADHD? Update on pharmacology and neuroimaging
What is ADHD? Update on pharmacology and neuroimagingWhat is ADHD? Update on pharmacology and neuroimaging
What is ADHD? Update on pharmacology and neuroimaging
 
Hanipsych, updates on neurobiology and neurotoxicity of depression
Hanipsych, updates on neurobiology and neurotoxicity of depressionHanipsych, updates on neurobiology and neurotoxicity of depression
Hanipsych, updates on neurobiology and neurotoxicity of depression
 
New treatment trends in alzheimer disease
New treatment trends in alzheimer diseaseNew treatment trends in alzheimer disease
New treatment trends in alzheimer disease
 
Danielle.Degroot.Case Study Pp
Danielle.Degroot.Case Study PpDanielle.Degroot.Case Study Pp
Danielle.Degroot.Case Study Pp
 
The neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarThe neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolar
 
A Multimodal, Regenerative Approach to Traumatic Brain Injury - OMED Oct 2020
A Multimodal, Regenerative Approach to Traumatic Brain Injury - OMED Oct 2020A Multimodal, Regenerative Approach to Traumatic Brain Injury - OMED Oct 2020
A Multimodal, Regenerative Approach to Traumatic Brain Injury - OMED Oct 2020
 
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDPsychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSD
 
Warren.Cognition.December.2008
Warren.Cognition.December.2008Warren.Cognition.December.2008
Warren.Cognition.December.2008
 
CBT_for_Bipolar_Disorder-Set_Available_for_Teaching.ppt
CBT_for_Bipolar_Disorder-Set_Available_for_Teaching.pptCBT_for_Bipolar_Disorder-Set_Available_for_Teaching.ppt
CBT_for_Bipolar_Disorder-Set_Available_for_Teaching.ppt
 
Schizophrenia~Ketamine~Pterostilbene
Schizophrenia~Ketamine~PterostilbeneSchizophrenia~Ketamine~Pterostilbene
Schizophrenia~Ketamine~Pterostilbene
 
Sublingual Immunotherapy From Efficacy, Safety to Practical Considerations
Sublingual Immunotherapy From Efficacy, Safety to Practical ConsiderationsSublingual Immunotherapy From Efficacy, Safety to Practical Considerations
Sublingual Immunotherapy From Efficacy, Safety to Practical Considerations
 
Sychosis and schizophrenia.pdf
Sychosis and schizophrenia.pdfSychosis and schizophrenia.pdf
Sychosis and schizophrenia.pdf
 
Depression-2010
Depression-2010Depression-2010
Depression-2010
 
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
Hans Jürgen-Current situation and future perspetives of antipsychotics in sch...
 
Psychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADPsychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SAD
 
Bogota delirium051110
Bogota delirium051110Bogota delirium051110
Bogota delirium051110
 
Brexpiprazole Final Presentation
Brexpiprazole Final PresentationBrexpiprazole Final Presentation
Brexpiprazole Final Presentation
 
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
 

More from Brian Piper

Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Brian Piper
 
Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Brian Piper
 
electronic cigarettes
electronic cigaretteselectronic cigarettes
electronic cigarettesBrian Piper
 
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Brian Piper
 
Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Brian Piper
 
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IISedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IIBrian Piper
 
Sedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part ISedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part IBrian Piper
 
Agents for Bipolar
Agents for BipolarAgents for Bipolar
Agents for BipolarBrian Piper
 
Anti Inflammation agents for CNS
Anti Inflammation agents for CNSAnti Inflammation agents for CNS
Anti Inflammation agents for CNSBrian Piper
 
Antidepressants Part II
Antidepressants Part IIAntidepressants Part II
Antidepressants Part IIBrian Piper
 
Anticonvulsants Part II
Anticonvulsants Part IIAnticonvulsants Part II
Anticonvulsants Part IIBrian Piper
 
Anticonvulsants Part I
Anticonvulsants Part IAnticonvulsants Part I
Anticonvulsants Part IBrian Piper
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain InjuryBrian Piper
 
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromePathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromeBrian Piper
 
Pathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadachePathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadacheBrian Piper
 
Pathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseasePathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseaseBrian Piper
 
Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Brian Piper
 
Pathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIPathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIBrian Piper
 
Pathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IPathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IBrian Piper
 

More from Brian Piper (20)

Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
 
Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014
 
electronic cigarettes
electronic cigaretteselectronic cigarettes
electronic cigarettes
 
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
 
Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013
 
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IISedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part II
 
Sedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part ISedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part I
 
Agents for Bipolar
Agents for BipolarAgents for Bipolar
Agents for Bipolar
 
Anti Inflammation agents for CNS
Anti Inflammation agents for CNSAnti Inflammation agents for CNS
Anti Inflammation agents for CNS
 
Antidepressants Part II
Antidepressants Part IIAntidepressants Part II
Antidepressants Part II
 
Anticonvulsants Part II
Anticonvulsants Part IIAnticonvulsants Part II
Anticonvulsants Part II
 
Anticonvulsants Part I
Anticonvulsants Part IAnticonvulsants Part I
Anticonvulsants Part I
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain Injury
 
ADHD Drugs
ADHD DrugsADHD Drugs
ADHD Drugs
 
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromePathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
 
Pathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadachePathophysiology: Migraine & Headache
Pathophysiology: Migraine & Headache
 
Pathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseasePathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's Disease
 
Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry
 
Pathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIPathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part II
 
Pathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IPathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part I
 

Recently uploaded

Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxEyobAlemu11
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxdrashraf369
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 

Recently uploaded (20)

Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptx
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptx
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 

Antipsychotics Part II

  • 1. Anti-psychotics II Brian J. Piper, Ph.D., M.S. piperbj@husson.edu February 4, 2013
  • 2. Goals • Pharmacy students should be able to: – describe the MOA and adverse effects of second generation antipsychotics – evaluate the relative pros and cons (acute and long-term) of first and second generation antipsychotics
  • 3. DSM5 Diagnosis of Schizophrenia • Two or more of the following, including 1, 2, or 3 1. Delusions 2. Hallucinations 3. Disorganized speech 4. Grossly abnormal psychomotor behavior 5. Negative symptoms • Duration: 1 month during last 6 • Social/occupational dysfunction • Exclusion: medical condition or drug
  • 4. Atypical (Second Generation) • Mechanism of Action – Dissociate more rapidly from the D2 receptor Stahl, S. (2008). Essential Psychopharmacology, p. 369-370.
  • 5. MOA of Atypical Antipsychotics • Dissociate more rapidly from the D2 receptor – ↓ acute EPS, ↓ hyperprolactinemia Stahl, S. (2008). Essential Psychopharmacology, p. 371.
  • 6. MOA of Atypicals • Atypicals – Dissociate more rapidly from the D2 receptor – Block the 5-HT2A (and so many other!) receptors Stahl, S. (2008). Essential Psychopharmacology, p. 384.
  • 7. 5-HT2A • Hallucinogens = 5-HT2A agonists • Receptor Distribution: cortex [11C]MDL100,907 Meyer et al. (2010). Neuroimage, 50(3), 984-993.
  • 8. Brain Morphology & Schizophrenia Some schizophrenia patients exhibit morphological changes in the brain like enlargement of fluid-filled ventricles.
  • 9. Adverse Effect of Atypicals I: Weight Gain
  • 10. Weight Gain & Olanzapine Weight Gain % of Patients Relative to Baseline (1.6 yrs) > 7% 64% > 15% 32% > 25% 12% Citrome et al. (2011). Journal of Clinical Investigation, 31(7), 455-482.
  • 11. Risks with long-term Atypicals Mechanism: 5-HT2C Mechanism: X $515 Million
  • 12. Concern • Adult monkeys received FGA (haloperidol) or * SGA (olanzapine) * antipsychotics for 2 years at doses similar to schizophrenics. • Gray matter in parietal cortex was examined. Konopaske et al. (2007). Neuropsychopharmacology, 32, 1216-1223.
  • 13. Do antipsychotics cause neurostructural changes? Repeated MRI of schizophrenics Ventricular volume change (slope) by antipsychotic treatment – most (+.39) – intermediate (+.36) – least (+.16) Beng-Choon et al. (2011). Archives of General Psychiatry, 68(2), 128-137.
  • 14. Do antipsychotics cause neurostructural changes? Repeated MRI of schizophrenics White matter change (slope) by antipsychotic treatment – most (-.64) – intermediate (-.51) – least (+1.30) Beng-Choon et al. (2011). Archives of General Psychiatry, 68(2), 128-137.
  • 15. Practice Makes Perfect • FGA: http://www.howjsay.com/index.php?word=perphenazine&submit=Submit • SGA: – http://www.howjsay.com/index.php?word=ziprasidone&submit=Submit – http://www.howjsay.com/index.php?word=quetiapine&submit=Submit – http://www.howjsay.com/index.php?word=risperidone&submit=Submit
  • 16. Clinical Antipsychotic Trials for Intervention Effectiveness) CATIE • 18-month randomized, double-blind trial of FGA & SGAs in real-world (N=1,432) funded by non-industry (NIMH) Perphenazine Olanzapine Risperidone Ziprasidone Quetiapine Discontinuation Rate 75% 64% 74% 79% 82% Weight Change (lbs/month) -0.2 +2.0 +0.4 -0.3 +0.5 Change in Cholesterol +1.5 +9.4 -1.3 -8.2 +6.6 Change in Prolactin = = ↑ = = Lieberman et al. (2005). New England Journal of Medicine, 353(12), 1209-1223.
  • 17. CATIE Findings • FGAs & SGAs showed similar efficacy with a slight advantage for olanzapine. • Olanzapine showed a higher metabolic risk relative to both FGA and other SGAs. Black Box For All SGAs
  • 18. Cognitive Behavioral Therapy • Antipsychotics show limited efficacy for negative symptoms & many patients continue to exhibit hallucinations & delusions • Cognitive Behavioral Therapy is a short-term, empirically based psychotherapy developed by Aaron “Tim” Beck (left) that is used with antipsychotics. 1921 - Rector & Beck (2012). J Nervous & Mental Disease, 200(10), 832-839.
  • 19.
  • 20. Onset Age • Males: early 20s • Females: late 20s
  • 21. Schizophrenia in Children • More frequently recognized • Example (0 to 3 min): http://www.youtube.com/watch?v=UTU Mt05_nCI :
  • 22. Summary • SGAs produce less acute EPS than FGA but also cause diabetes. • No clear consensus exists in the choice between FGA and SGA. • Using agents at above recommended doses or combining drugs are common clinically but are not well studied.
  • 23. Receptor/Adverse Effect X: diabetes M1: sedation H1: sedation, appetite α1: sedation 5-HT2C: appetite Stahl, S. (2008). Essential Psychopharmacology, p. 384.
  • 24. Self-Test #1 • _________ were the top selling drugs in 2009. – A) antipsychotics – B) oncology agents – C) antidiabetics – D) respiratory agents – E) HIV antivirals http://www.nytimes.com/2010/10/03/business/03psych.html?_r=4&hp=&pagewanted=all& http://survivingantidepressants.org/index.php?/topic/2963-the-top-prescription-drugs-of-2011/
  • 25. Self-Test #2 • If a family member were diagnosed with schizophrenia, what agent would you prefer they receive and why? Would this differ based on age or health?

Editor's Notes

  1. This change in thinking was originally quite revolutionary. The conventional wisdom was that a drug needed to generate EPS (pseudo-Parkinson’s, dystonia, akathisia) in order to produce a clinical (anti-psychotic) effect. The reduced prolactin effect is overall as some SGA’s (risperidone) still have pronounced effects.
  2. X: receptor involved with insulin resistance.
  3. LSD, psilocin (found in mushrooms), and mescaline (found in cacti) activate 5-HT2A.
  4. Mean weight gain during this period was 5.6 kg in this meta-analysis.
  5. http://www.nytimes.com/2010/10/03/business/03psych.html?_r=4&hp=&pagewanted=all&“Lilly paid a $515 million criminal fine as part of a broader, $1.4 billion settlement with the government” in 2009. This was the largest fine paid by a corporation to date.
  6. There was a smaller relationship between SCZ severity and structural changes. This structural changes were not due to extent of alcohol/drug use.
  7. Quetiapine is also a 5-HT1A partial agonist.
  8. The dose range of olanzapine was above that in the package insert! A metabolite of Perphenazine has some 5-HT2A affinity making it an odd choice of FGA.Patients in the olanzapine group gained more weight than patients in any other group, with an average weight gain of 2 lb (0.9 kg) per month!Ziprasidone (ziprasi doe n): http://www.howjsay.com/index.php?word=ziprasidone&submit=SubmitPerphenazine (per fen a zEne): http://www.howjsay.com/index.php?word=perphenazine&submit=Submit
  9. There is no psychiatric disorder with aggression as the key feature but antipsychotics are often used off label for this.
  10. #1 in terms of profits. This has slipped to #5 in 2011 (18.2 Billion versus 23 Billion for oncology).